‘Incremental’ Benefit Of Lumicell’s Cancer Imaging Drug Outweighs Manageable Risk, FDA Panel Says

 
• By Sarah Karlin-Smith
close up of person with breast surgery scar
FDA panel supported approval of imaging drug that should help avoid repeat breast cancer surgeries • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers